Pfizer Takeover Makes Dent in a $32 Billion Stock-Market Slump

image

(Bloomberg) — Pfizer Inc.’s acquisition of ReViral Ltd. chipped away at the drug maker’s stock-market slump.

The company’s shares gained 4.3% Thursday after the announcement that it was buying the lung-focused biotech firm for as much as $525 million, bucking the broader market’s drop.

But the shares are still down almost 7% this year — cutting some $32 billion from its market value — amid investor concern about the loss of revenue as drug patents expire and the uncertain fate of its booster shots as the Covid-19 pandemic winds down. That’s left the company trading at a discount to health-care peers that have been hitting record highs as investors turn to defensive bets amid geopolitical turmoil and an uncertain economic outlook.

Wall Street is itching for Pfizer to act to shore up growth, potentially by utilizing the $150 billion of capacity that Bank of Montreal estimates it has for acquisitions. Yet Thursday’s deal for a closely-held drug developer, ReViral Ltd. is likely too small to do much to change the pharmaceutical behemoth’s outlook.

“While we are encouraged with M&A in BioPharma, this is not exactly the deal we had hoped for,” BMO analyst Evan David Seigerman Seigerman wrote.

Big drugmakers have been eschewing large deals in favor of partnerships or buyouts of smaller companies. That helped drive merger activity for the sector during the first quarter to the slowest since the immediate aftermath of the pandemic in 2020.

Chris Schott an analyst with JPMorgan Chase & Co., said Pfizer is “the most controversial name” among the large-cap drugmakers, with bulls pointing to the company’s Covid vaccines and ability to deploy large amounts of capital and bears saying its valuation is still too high given the company’s core business beyond the coronavirus inoculations.

Excluding Pfizer’s Covid-19 vaccine and antiviral sales, Schott sees negative compound annual sales and earnings growth through 2025 as the company faces one of the indstry’s biggest revenue losses due to patent expirations.

Still, with Pfizer’s stock up investors appear to support the acquisition, which builds on gene-therapy partnerships forged in January. Truist’s Robyn Karnauskas said the deal could signal “a potential return to M&A, especially in an environment where companies seem to face hurdles going public.”

©2022 Bloomberg L.P.

 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Software Stocks To Buy Now

    International Business Machines Corporation (IBM) International Business Machines Corporation (IBM) is a global leader in cloud computing, AI, and enterprise software. The company provides IT infrastructure, cybersecurity, and quantum computing... Read More

  • 3 Food Stocks To Buy Now

    The Campbell’s Company (CPB) The Campbell’s Company is a leading producer of packaged foods and beverages, known for its soups, sauces, and snacks. With brands like Campbell’s, Pepperidge Farm, and... Read More

  • 3 Utility Stocks To Buy Now

    IDACORP, Inc. (IDA) IDACORP, Inc. is a utility holding company that provides electricity through its subsidiary, Idaho Power. The company focuses on renewable energy initiatives, grid modernization, and sustainable power... Read More

  • 3 Biotechnology Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative injectable drug formulations. Its proprietary technology enhances drug stability and... Read More

  • 3 Consumer Service Stocks To Buy Now

    TripAdvisor, Inc. (TRIP) TripAdvisor, Inc. operates the world’s largest travel guidance platform, offering user-generated reviews, price comparisons, and booking services for hotels, attractions, and restaurants worldwide. Chart Wynn Resorts, Limited... Read More

  • 3 Software Stocks To Buy Now

    Udemy, Inc. (UDMY) Udemy, Inc. is an online learning platform offering a vast catalog of courses across various fields. The company connects learners with expert instructors, providing affordable and accessible... Read More

  • 3 Energy Stocks To Buy Now

    Ranger Energy Services, Inc. (RNGR) Ranger Energy Services, Inc. provides well services and support for oil and gas production. The company specializes in high-spec rig solutions, completion services, and workover... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    ACADIA Pharmaceuticals Inc. (ACAD) ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s lead product, NUPLAZID, is used to treat Parkinson’s... Read More